Mar 22, 2021 10:44am EDT ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
Feb 02, 2021 8:30am EST ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Nov 09, 2020 6:30am EST ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
Oct 30, 2020 6:30am EDT ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium